Rapid Micro Biosystems is at the forefront of developing and providing groundbreaking technologies that fully automate and accelerate monitoring and detection of microbial contamination for the biopharmaceutical manufacturing industry. The company’s automated, high-throughput Growth Direct™ platform replaces slow, error-prone, manual QC processes, allowing manufacturers to confidently accelerate bioprocessing, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity.  The platform has been adopted by more than half of the top twenty biopharmaceutical companies and is being leveraged by industry leaders in their commercial manufacture of groundbreaking therapeutics including immunotherapies and cell therapies.